Researchers from the lab of Mariella Filbin, MD, PhD, in collaboration with Michigan Medicine and the Medical University of Vienna, explore a potential new use for Avapritinib in treating aggressive gliomas. Learn more: bit.ly/4bJmTBk

1/✨New study out in Cell Reports Medicine ! - LaBelle & Haase et al. 2025 🧠🔬 Let's dive in to our latest collaborative work with Mariella Filbin & Kai Wucherpfennig! cell.com/cell-reports-m…

Excited to see our latest study on the immune landscape of pediatric high-grade glioma patients out! Tweetorial from fabulous Rebecca Pötschke below 👇🏻, we hope this will useful to many in the field! Dana-Farber/Boston Children's Boston Children's Dana-Farber Broad Institute #endbraincancer

1/ Thrilled to share our TWO back-to-back papers published in Nature Genetics today! nature.com/articles/s4158… , nature.com/articles/s4158…

We are delighted to share our new study on metabolic dependencies in group-3 medulloblastoma! Thanks to an awesome team of collaborators who made this possible! Lyssiotis Lab Shah Lab The Sontag Foundation Carl Koschmann Sophia Lunt U-M Rogel Cancer Center Michigan Pathology cell.com/cancer-cell/ab…

In a medical milestone, a customized base editor was developed, characterized in human and mouse cells, tested in mice, studied for safety in non-human primates, cleared by U.S. FDA for clinical trial use, manufactured as a complex with an LNP, and dosed into a baby with a severe,

May is Brain Cancer Awareness Month. New research from the lab of Mariella Filbin, MD, PhD, suggests that avapritinib, an FDA-approved drug used to treat GI tumors, could also treat high-grade gliomas. Learn more. bit.ly/4j7pBm3

Biggest congrats to Lisa, Alex and team for this beautiful work and the important insights into the biology of ETMR, a rare but highly aggressive childhood brain tumor!